PDF(Pubmed)
Abstract：
UNASSIGNED: The aim was to investigate whether the stem cell marker LGR6 has prognostic value in colon cancer, alone or in combination with the prognostic biomarkers CEA and CXCL16.
UNASSIGNED: LGR6 mRNA levels were determined in 370 half lymph nodes of 121 colon cancer patients. Ability to predict relapse after curative surgery was estimated by Kaplan-Meier survival model and Cox regression analyses.
UNASSIGNED: Patients with high LGR6 levels [LGR6(+)] had a decreased mean survival time of 11 months at 5-year follow-up and 47 months at 12-year follow-up, respectively, with hazard ratios of 3.2 and 2.8. LGR6 mRNA analysis added prognostic value to CEA and CXCL16 mRNA analysis. In the poor prognosis groups CEA(+) and CXCL16(+), further division was achieved by LGR6 analysis. LGR6(+) patients had a very poor prognosis. LGR6 also identified a small number of CEA(-), TNM stage I patients who relapsed suggesting stem cell origin of these tumors. LGR6 and LGR5 levels correlated strongly in lymph nodes of stage I and IV patients but not in stage II patients, suggesting that these stem cell markers are differentially regulated.
UNASSIGNED: This study highlights LGR6 as a useful prognostic biomarker independently and in combination with CEA, CXCL16 or LGR5 identifying different risk groups.
UNASSIGNED: LGR6 mRNA levels were determined in 370 half lymph nodes of 121 colon cancer patients. Ability to predict relapse after curative surgery was estimated by Kaplan-Meier survival model and Cox regression analyses.
UNASSIGNED: Patients with high LGR6 levels [LGR6(+)] had a decreased mean survival time of 11 months at 5-year follow-up and 47 months at 12-year follow-up, respectively, with hazard ratios of 3.2 and 2.8. LGR6 mRNA analysis added prognostic value to CEA and CXCL16 mRNA analysis. In the poor prognosis groups CEA(+) and CXCL16(+), further division was achieved by LGR6 analysis. LGR6(+) patients had a very poor prognosis. LGR6 also identified a small number of CEA(-), TNM stage I patients who relapsed suggesting stem cell origin of these tumors. LGR6 and LGR5 levels correlated strongly in lymph nodes of stage I and IV patients but not in stage II patients, suggesting that these stem cell markers are differentially regulated.
UNASSIGNED: This study highlights LGR6 as a useful prognostic biomarker independently and in combination with CEA, CXCL16 or LGR5 identifying different risk groups.
摘要：
■目的是研究干细胞标志物LGR6在结肠癌中是否具有预后价值，单独或与预后生物标志物CEA和CXCL16组合。
■在121例结肠癌患者的370个半淋巴结中测定LGR6mRNA水平。通过Kaplan-Meier生存模型和Cox回归分析估计治愈性手术后复发的预测能力。
■LGR6水平高[LGR6(+)]的患者在5年随访时平均生存时间减少了11个月，在12年随访时平均生存时间减少了47个月，分别,危险比为3.2和2.8。LGR6mRNA分析增加了CEA和CXCL16mRNA分析的预后价值。在预后不良组CEA（+）和CXCL16（+），通过LGR6分析实现了进一步的划分.LGR6(+)患者预后极差。LGR6还确定了少量CEA(-)，复发的TNMI期患者提示这些肿瘤的干细胞起源。LGR6和LGR5水平在I期和IV期患者的淋巴结中密切相关，但在II期患者中没有，这表明这些干细胞标记是有差异调节的。
■本研究强调LGR6作为一个有用的预后生物标志物独立和与CEA组合，CXCL16或LGR5识别不同的风险组。
■在121例结肠癌患者的370个半淋巴结中测定LGR6mRNA水平。通过Kaplan-Meier生存模型和Cox回归分析估计治愈性手术后复发的预测能力。
■LGR6水平高[LGR6(+)]的患者在5年随访时平均生存时间减少了11个月，在12年随访时平均生存时间减少了47个月，分别,危险比为3.2和2.8。LGR6mRNA分析增加了CEA和CXCL16mRNA分析的预后价值。在预后不良组CEA（+）和CXCL16（+），通过LGR6分析实现了进一步的划分.LGR6(+)患者预后极差。LGR6还确定了少量CEA(-)，复发的TNMI期患者提示这些肿瘤的干细胞起源。LGR6和LGR5水平在I期和IV期患者的淋巴结中密切相关，但在II期患者中没有，这表明这些干细胞标记是有差异调节的。
■本研究强调LGR6作为一个有用的预后生物标志物独立和与CEA组合，CXCL16或LGR5识别不同的风险组。
